IASLC 2020 World Conference on Lung Cancer Singapore: Highlights

meeting/webinar banner
Overview

Listen to the Conference Chairs Discuss Highlights from WCLC 2020. 

In this live webinar Dr. Yi-long Wu, Dr. Daniel Tan and Dr. Ross Soo will discuss key abstracts, presentations, and developments reported during the 2020 World Conference on Lung Cancer Singapore. 

6 am MST
8 am EST
9 pm/21:00 SST (Singapore Standard Time)

1 hour webinar: Three presentations followed by a Q and A.

Date
Feb 22, 2021 -
Feb 22, 2021
CME Accredited
Yi-Long Wu
Yi-long Wu, MD

Yi-long Wu, MD
Head of Department
Guangdong Lung Cancer Institute
Guangdong General Hospital and Guangdong Academy of Medical Sciences

 

 

 

 

 

 

 

 

Daniel Tan
Daniel SW Tan, MD 

Daniel SW Tan, MD 
Senior Consultant
Division of Medical Oncology 
National Cancer Centre Singapore

 

 

 

 

 

 

 

 

Ross Soo
Ross Soo, MBBS, RACP

Ross Soo, MBBS, RACP
Senior Consultant at the Department of Haematology-Oncology, NCIS
Adjunct Principal Investigator, Cancer Science Institute of Singapore, NUS

At the conclusion of this activity, participants will be able to:

  • Describe scientific progress in the prevention, early detection, diagnosis and treatment of thoracic malignancies.
  • Explain advances in the multidisciplinary management of patients in relation to current standards of care.
  • Identify the most relevant clinical research results and ongoing trials likely to impact patient care in the near future.

This webinar is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.

Accreditation Statement

The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The International Association for the Study of Lung Cancer designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Daniel Tan:

Advisory Board: Novartis, Bayer, Boehringer Ingelheim, Astra Zeneca, Eli-lily, Loxo, Pfizer, MSD. Contracted/Support research grant: Novartis, Astra Zeneca, GlaxoSmithKline, Bayer, Pfizer.

Yi-long Wu:

Advisory Board: AstraZeneca, Boehringer Ingelheim. Honorarium received from promotional activities: AstraZeneca, Roche, Boehringer Ingelheim, Pfizer, BMS, MSD, Eli Lilly (all not promotional activities). Contracted/Support Research Grant: AstraZeneca, Roche, Boehringer Ingelheim. 

Ross Soo:

Contracted/Support research grant: AstraZeneca, and Boehringer Ingelheim. Personal fees: Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer,Roche, Taiho, Takeda, Yuhan, Amgen.

Joachim Aerts, MD, PhD: 

Advisory Board: BMS, Roche, Eli-Lilly, Boehringer Ingelheim, Takeda, MSD, Astra Zeneca and Amphera. Ownership/Stock Interest: Amphera.  Royalty or Intellectual Property Holder: Allogenic tumor-cell Lysate, Combination immunotherapy in oncology, Biomarker for immuno-oncology.

None of the other individuals involved in the planning or review of the activity have disclosed any relevant financial relationships.

Yi-Long Wu
Yi-long Wu, MD

Yi-long Wu, MD
Head of Department
Guangdong Lung Cancer Institute
Guangdong General Hospital and Guangdong Academy of Medical Sciences

 

 

 

 

 

 

 

 

Daniel Tan
Daniel SW Tan, MD 

Daniel SW Tan, MD 
Senior Consultant
Division of Medical Oncology 
National Cancer Centre Singapore

 

 

 

 

 

 

 

 

Ross Soo
Ross Soo, MBBS, RACP

Ross Soo, MBBS, RACP
Senior Consultant at the Department of Haematology-Oncology, NCIS
Adjunct Principal Investigator, Cancer Science Institute of Singapore, NUS

At the conclusion of this activity, participants will be able to:

  • Describe scientific progress in the prevention, early detection, diagnosis and treatment of thoracic malignancies.
  • Explain advances in the multidisciplinary management of patients in relation to current standards of care.
  • Identify the most relevant clinical research results and ongoing trials likely to impact patient care in the near future.

This webinar is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.

Accreditation Statement

The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The International Association for the Study of Lung Cancer designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Daniel Tan:

Advisory Board: Novartis, Bayer, Boehringer Ingelheim, Astra Zeneca, Eli-lily, Loxo, Pfizer, MSD. Contracted/Support research grant: Novartis, Astra Zeneca, GlaxoSmithKline, Bayer, Pfizer.

Yi-long Wu:

Advisory Board: AstraZeneca, Boehringer Ingelheim. Honorarium received from promotional activities: AstraZeneca, Roche, Boehringer Ingelheim, Pfizer, BMS, MSD, Eli Lilly (all not promotional activities). Contracted/Support Research Grant: AstraZeneca, Roche, Boehringer Ingelheim. 

Ross Soo:

Contracted/Support research grant: AstraZeneca, and Boehringer Ingelheim. Personal fees: Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer,Roche, Taiho, Takeda, Yuhan, Amgen.

Joachim Aerts, MD, PhD: 

Advisory Board: BMS, Roche, Eli-Lilly, Boehringer Ingelheim, Takeda, MSD, Astra Zeneca and Amphera. Ownership/Stock Interest: Amphera.  Royalty or Intellectual Property Holder: Allogenic tumor-cell Lysate, Combination immunotherapy in oncology, Biomarker for immuno-oncology.

None of the other individuals involved in the planning or review of the activity have disclosed any relevant financial relationships.

Share